New drug duo aims to tackle tough lymphoma
NCT ID NCT03323151
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured how many patients achieved a complete remission within the first year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ixazomib (Ninlaro) and ibrutinib (Imbruvica)
What this could lead to
If this combination works well, it could offer a new treatment option for people with mantle cell lymphoma that has come back or stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 43 participants, so results may not apply to everyone. Side effects from the drug combination could be serious, and the added benefit of ixazomib over ibrutinib alone is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carle Cancer Center
Urbana, Illinois, 61801, United States
-
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912, United States
-
Gundersen Health System
La Crosse, Wisconsin, 54601, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU
New York, New York, 10016, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
ProHealth Care
Waukesha, Wisconsin, 53188, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Kansas
Overland Park, Kansas, 66210, United States
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
West Virginia University
Morgantown, West Virginia, 26506, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States